Nuvation Bio (NUVB) bounces back 12% on impressive clinical trial result

MSN
2025.12.04 18:19
portai
I'm PortAI, I can summarize articles.

Nuvation Bio Inc. (NYSE:NUVB) saw its stock rise by 12.05% to $8.37 following positive phase 2 clinical trial results for Safusidenib, a treatment for a type of brain tumor.

Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer